GWS
CRSP icon

Greykasell Wealth Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Greykasell Wealth Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.23K Hold
68
– – ﹤0.01% 495
2025
Q4 		$3.57K Hold
68
– – ﹤0.01% 428
2025
Q3 		$4.41K Hold
68
– – ﹤0.01% 346
2025
Q2 		$3.31K Hold
68
– – ﹤0.01% 292
2025
Q1 		$2.31K Buy
+68
New +$2.88K ﹤0.01% 327

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Greykasell Wealth Strategies's CRSP Position: Q1 2026 in Review

Greykasell Wealth Strategies held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 68 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #495.

Greykasell Wealth Strategies first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.41K in Q3 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Greykasell Wealth Strategies held 68 shares of CRISPR Therapeutics worth $3.23K as of Q1 2026.
  • Greykasell Wealth Strategies left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #495 holding.
  • Greykasell Wealth Strategies first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Greykasell Wealth Strategies's CRISPR Therapeutics position peaked at $4.41K in Q3 2025.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.